Alexion Pharmaceuticals (NASDAQ:ALXN) reported Q2 EPS of $0.29, ahead of consensus estimates of $0.26 per share. Revenues rose 47.6% year-over-year to $185.7 million, topping consensus estimates of $178.0 million.
The company sees 2011 EPS of $1.10 to $1.15, up from a previous range of $1.05 to $1.12 per share, vs. consensus estimates of $1.14 per share, on revenues of $745 to $755 million, up from a previous range of $720 to $740 million, vs. consensus estimates of $740.04 million.
Leonard Bell, M.D., Chief Executive Officer of Alexion said, "In the second quarter, we continued to serve a growing number of new patients with PNH in our core territories of the US, Western Europe and Japan. During Q2, we also focused on responding to the urgent public health crisis related to the STEC-HUS outbreak in Germany. Towards the end of this year, we expect to complete the aHUS regulatory process in the US and are likewise focused on further accelerating the development of our pipeline portfolio, which now comprises the widest group of compounds and ultra-rare disorders in our history."